Search Results for

EA5182

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Bladder/Urinary Tract Cancer  (4)    Adjuvant  (1)    Metastatic  (1) Brain  (9)    Glioblastoma Multiforme (GBM)  (2)    Other Brain Tumors  (3) Breast  (15)    Breast Cancer Adjuvant  (1)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (16) Carcinoid Tumors  (2) Colorectal Cancer  (5)    Rectal Neoadjuvant  (1) Esophageal Cancer  (5) Gastric Cancer  (4) Head/Neck Cancer  (9) Leukemia  (5)    Acute Myeloid Leukemia (AML)  (2)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (2) Lung Cancer  (14)    Non-Small Cell Lung Cancer  (10)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (1)       Adjuvant Treatment for Resected NSCLC  (1)    Small Cell Lung Cancer  (3)       Extensive Stage SCLC  (1) Lymphoma  (3)    Non-Hodgkin’s Lymphoma  (3)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (2) MATCH Trial  (3) Melanoma  (3)    Metastatic  (1) Misc. Gynecology  (4) Multiple Myeloma  (3) Ovarian  (2) Pancreatic  (8)    Metastatic Disease  (1) Prostate  (10) Renal Cell/Kidney Cancer  (2) Sarcoma  (1) Thyroid  (1)